These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 21342037)

  • 1. Irosustat: a first-generation steroid sulfatase inhibitor in breast cancer.
    Palmieri C; Januszewski A; Stanway S; Coombes RC
    Expert Rev Anticancer Ther; 2011 Feb; 11(2):179-83. PubMed ID: 21342037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steroid sulfatase: a new target for the endocrine therapy of breast cancer.
    Stanway SJ; Delavault P; Purohit A; Woo LW; Thurieau C; Potter BV; Reed MJ
    Oncologist; 2007 Apr; 12(4):370-4. PubMed ID: 17470679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patients.
    Nakata T; Takashima S; Shiotsu Y; Murakata C; Ishida H; Akinaga S; Li PK; Sasano H; Suzuki T; Saeki T
    J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):455-60. PubMed ID: 14623544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of tamoxifen or anastrozole on steroid sulfatase activity and serum androgen concentrations in postmenopausal women with breast cancer.
    Stanway SJ; Palmieri C; Stanczyk FZ; Folkerd EJ; Dowsett M; Ward R; Coombes RC; Reed MJ; Purohit A
    Anticancer Res; 2011 Apr; 31(4):1367-72. PubMed ID: 21508387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steroid sulfatase inhibitors for estrogen- and androgen-dependent cancers.
    Purohit A; Foster PA
    J Endocrinol; 2012 Feb; 212(2):99-110. PubMed ID: 21859802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of steroid sulfatase inhibitors.
    Woo LW; Purohit A; Potter BV
    Mol Cell Endocrinol; 2011 Jul; 340(2):175-85. PubMed ID: 21238537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor.
    Stanway SJ; Purohit A; Woo LW; Sufi S; Vigushin D; Ward R; Wilson RH; Stanczyk FZ; Dobbs N; Kulinskaya E; Elliott M; Potter BV; Reed MJ; Coombes RC
    Clin Cancer Res; 2006 Mar; 12(5):1585-92. PubMed ID: 16533785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steroid sulfatase inhibitors: promising new tools for breast cancer therapy?
    Geisler J; Sasano H; Chen S; Purohit A
    J Steroid Biochem Mol Biol; 2011 May; 125(1-2):39-45. PubMed ID: 21356310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steroid sulfatase: a pivotal player in estrogen synthesis and metabolism.
    Purohit A; Woo LW; Potter BV
    Mol Cell Endocrinol; 2011 Jul; 340(2):154-60. PubMed ID: 21693170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steroid sulfatase: molecular biology, regulation, and inhibition.
    Reed MJ; Purohit A; Woo LW; Newman SP; Potter BV
    Endocr Rev; 2005 Apr; 26(2):171-202. PubMed ID: 15561802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steroid sulfatase inhibition success and limitation in breast cancer clinical assays: An underlying mechanism.
    Sang X; Han H; Poirier D; Lin SX
    J Steroid Biochem Mol Biol; 2018 Oct; 183():80-93. PubMed ID: 29803725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer.
    Dodwell D; Vergote I
    Cancer Treat Rev; 2005 Jun; 31(4):274-82. PubMed ID: 15908126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen O-sulfamates and their analogues: Clinical steroid sulfatase inhibitors with broad potential.
    Thomas MP; Potter BV
    J Steroid Biochem Mol Biol; 2015 Sep; 153():160-9. PubMed ID: 25843211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
    McKeage K; Curran MP; Plosker GL
    Drugs; 2004; 64(6):633-48. PubMed ID: 15018596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents.
    Vergote I; Abram P
    Ann Oncol; 2006 Feb; 17(2):200-4. PubMed ID: 16251200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent active site-directed inhibition of steroid sulphatase by tricyclic coumarin-based sulphamates.
    Woo LL; Purohit A; Malini B; Reed MJ; Potter BV
    Chem Biol; 2000 Oct; 7(10):773-91. PubMed ID: 11033081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women.
    Cardoso F; Bischoff J; Brain E; Zotano ÁG; Lück HJ; Tjan-Heijnen VC; Tanner M; Aapro M
    Cancer Treat Rev; 2013 Aug; 39(5):457-65. PubMed ID: 22840697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of estrone sulfatase and its inhibitors--an important new target against hormone dependent breast cancer.
    Ahmed S; Owen CP; James K; Sampson L; Patel CK
    Curr Med Chem; 2002 Jan; 9(2):263-73. PubMed ID: 11860358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00).
    Perey L; Paridaens R; Hawle H; Zaman K; Nolé F; Wildiers H; Fiche M; Dietrich D; Clément P; Köberle D; Goldhirsch A; Thürlimann B
    Ann Oncol; 2007 Jan; 18(1):64-69. PubMed ID: 17030543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steroid metabolism in breast cancer.
    Foster PA
    Minerva Endocrinol; 2008 Mar; 33(1):27-37. PubMed ID: 18277377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.